Weihua Hu

Weihua Hu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
SWSimin Wu
Simin Wu
WHWeihua Hu
Weihua Hu
WXWei Xiao
Wei Xiao
YLYongxia Li
Yongxia Li
YHYan Huang
Yan Huang
XZXu Zhang
Xu Zhang
Gardnerella vaginalis is a pathogen responsible for bacterial vaginosis, which is commonly found in female vaginas and rarely causes infections outside the female genitalia. Here, we report the use of metagenomic next-generation sequencing (mNGS) to detect and confirm pulmonary infection and pleural effusion caused by G. vaginalis in a 47-year-old man. The patient’s symptoms and imaging improved after 2 weeks of oral ornidazole, and he was cured after 3 months. Overall, the findings of this case demonstrate that mNGS is a useful tool for diagnosis of unexplained lung infections and pleural effusions. Its effectiveness in rapid and accurate etiological diagnosis and monitoring of diseases can allow detection of the etiology of difficult cases that return negative results after traditional cultures.

21 October 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
XDXiaoyue Deng
Xiaoyue Deng
ZYZhiqiong Yu
Zhiqiong Yu
WHWeihua Hu
Weihua Hu
The FAT atypical cadherin (FAT) gene family comprises FAT atypical cadherin 1 (FAT1), 2 (FAT2), 3 (FAT3), and 4 (FAT4). These transmembrane adhesion proteins are essential for regulating cell polarity, adhesion, and migration, and are involved in multiple signaling transduction pathways. With the advancement of tumor genomics research, the mutation, expression, and functional regulation of FAT in various cancer types have been elucidated, particularly in non-small cell lung cancer, where FAT has significant biological implications and promising clinical applications. FAT1, a frequently mutated member of the family, participates in remodeling the immune microenvironment via the Wnt/β-catenin, Hippo, and transforming growth factor-beta (TGF-β) pathways. It also influences immune cell infiltration, immune checkpoint expression, and tumor mutational burden, thereby affecting the efficacy of immunotherapy. FAT2 influences cell migration and immune response by modulating cytoskeletal dynamics and the expression of immunochemokines. The non-coding RNA circular RNA FAT3 (circFAT3) may contribute to tumor growth and metastasis. FAT4, a major upstream regulator of the Hippo signaling pathway, inhibits Yes-associated protein/transcriptional coactivator with PDZ-binding motif, maintains cell polarity, and plays multiple roles by regulating the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) pathways and promoting anti-immune escape. This study comprehensively integrated and analyzed research results on the characteristics of the FAT gene family in lung cancer, focusing on its mutations, signaling pathways, and immunological roles, as well as its clinical significance in terms of prognosis. This study provides theoretical support and references for the development of targeted therapeutic strategies.

4 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
GQGuoqing Qian
Guoqing Qian
YZYong Zhang
Yong Zhang
YXYang Xu
Yang Xu
WHWeihua Hu
Weihua Hu
IHIan P Hall
Ian P Hall
JMjin mei
jin mei
Summary: Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children is associated with better outcomes than in adults. The inflammatory response to COVID-19 infection in children remains poorly characterised. Methods: We retrospectively analysed the medical records of 127 laboratory-confirmed COVID-19 patients aged 1 month to 16 years from Wuhan and Jingzhou of Hubei Province. Patients presented between January 25 th and March 24 th 2020. Information on clinical features, laboratory results, plasma cytokines/chemokines and lymphocyte subsets were analysed. Findings: Children admitted to hospital with COVID-19 were more likely to be male (67.7%) and the median age was 7.3 [IQR 4.9] years. All but one patient with severe disease was aged under 2 and the majority (5/7) had significant co-morbidities. Despite 53% having viral pneumonia on CT scanning only 2 patients had low lymphocyte counts and no differences were observed in the levels of plasma proinflammatory cytokines, including interleukin (IL)-2, IL-4, IL-6, tumour necrosis factor (TNF)- α , and interferon (IFN)- γ between patients with mild, moderate or severe disease. Interpretations: We demonstrated that the immune responses of children to COVID-19 infection is significantly different from that seen in adults. Our evidence suggests that SARS-CoV-2 does not trigger a robust inflammatory response or ‘cytokine storm’ in children with COVID-19, and this may underlie the generally better outcomes seen in children with this disease. These data also imply anti-cytokine therapies may not be effective in children with moderate COVID-19. Funding: This study was funded by National Natural Foundation of China (No. 81970653). Research in context: Evidence before this study: We searched PubMed without language restriction for studies published until June 25, 2020, using the search terms “SARS-CoV-2” or “novel coronavirus” or “COVID-19” and “immune responses” or “innate immunity” or “cytokine” or “subset of lymphocyte” and “children” or “adolescent”. Previously published research describes that severe and fatal cases in children are relatively rare. However, the inflammatory responses to COVID-19 infection in children remains poorly characterised. Added value of this study: We analysed data from 127 laboratory-confirmed COVID-19 patients aged 1 month to 16 years in Hubei province to explore the immune responses to SARS-CoV-2 infection presenting to hospital with COVID-19. Cell numbers of CD3+, CD4+, CD8+ and natural killer T cells were within mostly normal limits even in more severe cases, and the levels of immunoglobulins, and proinflammatory cytokines, including interleukin (IL)-2, IL-4, IL-6, tumour necrosis factor (TNF)-α, and interferon (IFN)-γ were not generally elevated regardless of disease severity. Implications of all the available evidence: The immune response to SARS-CoV-2 infection of children is significantly different from that seen in adults. The inflammatory responses seen even in children with viral pneumonia on CT are relatively mild and do not trigger the “cytokine storm” seen in some adults with COVID-19. This implies anti-cytokine therapies may not be effective in children with COVID-19.